British Journal of Cancer最新文献

筛选
英文 中文
Complete blood count-derived inflammation indices in colorectal cancer: head-to-head case-control and prognostic analyses with population reference intervals and external replication. 结直肠癌的全血细胞计数衍生炎症指标:有人群参考区间和外部复制的病例对照和预后分析
IF 7.8 1区 医学
British Journal of Cancer Pub Date : 2026-10-24 DOI: 10.1038/s41416-026-03647-z
Eun Kyung Choe, Min Jung Kim, Dong Woon Lee, Sung Chan Park, Dae Kyung Sohn, Jae Hwan Oh, Seung-Bum Ryoo, Seung-Yong Jeong, Kyu Joo Park, Ji Won Park
{"title":"Complete blood count-derived inflammation indices in colorectal cancer: head-to-head case-control and prognostic analyses with population reference intervals and external replication.","authors":"Eun Kyung Choe, Min Jung Kim, Dong Woon Lee, Sung Chan Park, Dae Kyung Sohn, Jae Hwan Oh, Seung-Bum Ryoo, Seung-Yong Jeong, Kyu Joo Park, Ji Won Park","doi":"10.1038/s41416-026-03647-z","DOIUrl":"https://doi.org/10.1038/s41416-026-03647-z","url":null,"abstract":"<p><strong>Background: </strong>Systemic inflammation drives cancer progression. We investigated the clinical utility of five routine complete blood count (CBC)-derived inflammatory biomarkers, neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), monocyte-lymphocyte ratio (MLR), systemic inflammation response index (SIRI), and systemic immune-inflammation index (SII), in colorectal cancer (CRC) patients.</p><p><strong>Methods: </strong>We performed head-to-head case-control and prognostic analyses of five indices in 2305 CRC patients and 78,281 health‑screening controls, with replication in 1031 CRC patients. Analyses included propensity score matching, Cox regression, restricted cubic splines, and Harrell's concordance index. Population reference intervals were derived, and cross‑population transferability was assessed using the National Health and Nutrition Examination Survey (NHANES).</p><p><strong>Results: </strong>All indices were elevated in CRC patients and independently associated with survival. MLR retained diagnostic and prognostic significance in Stage I disease and was replicated. Dose-response trends were observed across quartiles, with non‑linear threshold effects for MLR and SIRI. Incremental prognostic gains beyond stage were modest. Reference intervals showed substantial overlap between CRC and healthy populations, limiting screening utility. NHANES comparison revealed non‑uniform transferability.</p><p><strong>Conclusion: </strong>CBC‑derived indices demonstrated reproducible diagnostic and prognostic relevance, with MLR particularly informative in early‑stage CRC. Reference intervals contextualise abnormality but should not be interpreted as CRC screening or treatment thresholds.</p>","PeriodicalId":9243,"journal":{"name":"British Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":7.8,"publicationDate":"2026-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149262884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Editorial Expression of Concern: Ligand-independent activation of EphA2 by arachidonic acid induces metastasis-like behaviour in prostate cancer cells. 编辑表达关注:花生四烯酸对EphA2的非配体激活诱导前列腺癌细胞的转移样行为。
IF 7.8 1区 医学
British Journal of Cancer Pub Date : 2026-10-22 DOI: 10.1038/s41416-026-03650-4
T Tawadros, M D Brown, C A Hart, N W Clarke
{"title":"Editorial Expression of Concern: Ligand-independent activation of EphA2 by arachidonic acid induces metastasis-like behaviour in prostate cancer cells.","authors":"T Tawadros, M D Brown, C A Hart, N W Clarke","doi":"10.1038/s41416-026-03650-4","DOIUrl":"https://doi.org/10.1038/s41416-026-03650-4","url":null,"abstract":"","PeriodicalId":9243,"journal":{"name":"British Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":7.8,"publicationDate":"2026-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149243049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Retraction Note: Statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, potentiate the anti-angiogenic effects of bevacizumab by suppressing angiopoietin2, BiP, and Hsp90α in human colorectal cancer. 注:他汀类药物,3-羟基-3-甲基戊二酰辅酶A还原酶抑制剂,通过抑制人类结直肠癌中的血管生成素2、BiP和Hsp90α来增强贝伐单抗的抗血管生成作用。
IF 7.8 1区 医学
British Journal of Cancer Pub Date : 2026-10-22 DOI: 10.1038/s41416-026-03656-y
S J Lee, I Lee, J Lee, C Park, W K Kang
{"title":"Retraction Note: Statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, potentiate the anti-angiogenic effects of bevacizumab by suppressing angiopoietin2, BiP, and Hsp90α in human colorectal cancer.","authors":"S J Lee, I Lee, J Lee, C Park, W K Kang","doi":"10.1038/s41416-026-03656-y","DOIUrl":"https://doi.org/10.1038/s41416-026-03656-y","url":null,"abstract":"","PeriodicalId":9243,"journal":{"name":"British Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":7.8,"publicationDate":"2026-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149243130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Inhibition of ACSS2 enhances cabozantinib sensitivity by blocking TFEB-induced autophagic flux in hepatocellular carcinoma. 抑制ACSS2通过阻断tfeb诱导的肝细胞癌自噬通量增强卡博赞替尼敏感性。
IF 7.8 1区 医学
British Journal of Cancer Pub Date : 2026-10-21 DOI: 10.1038/s41416-026-03538-3
Xuping Feng, Jiang Lan, Jinpeng Du, Chuang Jiang, Guoteng Qiu, Yujia Song, Xinyi Zhou, Zheng Zhang, Lin Xu, Die Hu, Yan Liang, Jiwei Huang, Yong Zeng, Kefei Yuan
{"title":"Inhibition of ACSS2 enhances cabozantinib sensitivity by blocking TFEB-induced autophagic flux in hepatocellular carcinoma.","authors":"Xuping Feng, Jiang Lan, Jinpeng Du, Chuang Jiang, Guoteng Qiu, Yujia Song, Xinyi Zhou, Zheng Zhang, Lin Xu, Die Hu, Yan Liang, Jiwei Huang, Yong Zeng, Kefei Yuan","doi":"10.1038/s41416-026-03538-3","DOIUrl":"https://doi.org/10.1038/s41416-026-03538-3","url":null,"abstract":"<p><strong>Background: </strong>Cabozantinib, a promising tyrosine kinase inhibitor (TKI), has recently been approved by the Food and Drug Administration (FDA) to treat hepatocellular carcinoma (HCC). However, the objective response rate (ORR) of cabozantinib as monotherapy is low. Therefore, there is an urgent need to develop cabozantinib-based combination therapy.</p><p><strong>Methods: </strong>RNA-sequencing was used to analyse the gene expression alterations in HCC cells after cabozantinib treatment. A luciferase reporter assay was used to measure TFEB transcriptional activity. In vitro and in vivo studies were applied to assess the effect of cabozantinib in combination with autophagy inhibitors on HCC.</p><p><strong>Results: </strong>Our results showed that cabozantinib induces autophagic flux, which protects HCC cells from cabozantinib-induced growth inhibition and apoptosis. Further mechanistic studies showed that cabozantinib upregulates Acetyl-CoA Synthetase 2 (ACSS2) and promotes its nuclear translocation, which subsequently activates transcription factor EB (TFEB). TFEB then binds to lysosomal and autophagy gene promoter regions, thereby promoting lysosomal biogenesis and inducing autophagy. In addition, the combination use of an ACSS2 inhibitor or chloroquine (CQ) enhances the antitumor efficacy of cabozantinib in HCC both in vitro and in vivo.</p><p><strong>Conclusion: </strong>Our study proposes a novel molecular mechanism of cabozantinib and provides insights into cabozantinib-based combination therapy for HCC.</p>","PeriodicalId":9243,"journal":{"name":"British Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":7.8,"publicationDate":"2026-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149236955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Spatial transcriptomic sequencing identifies lipid metabolism and mitochondrial respiration as central features of T cell excluded esophageal adenocarcinomas. 空间转录组测序确定脂质代谢和线粒体呼吸是T细胞排除的食管腺癌的中心特征。
IF 7.8 1区 医学
British Journal of Cancer Pub Date : 2026-10-21 DOI: 10.1038/s41416-026-03635-3
Jasper Sanders, Nico Hahn, Emma N Bos, Deni M van Schie, Isaac J Nijman, Nicole C T van Grieken, Donald L van der Peet, Hanneke W M van Laarhoven, Joep Grootjans, Maarten F Bijlsma, Jan Van den Bossche, Tanja D de Gruijl, Sarah Derks
{"title":"Spatial transcriptomic sequencing identifies lipid metabolism and mitochondrial respiration as central features of T cell excluded esophageal adenocarcinomas.","authors":"Jasper Sanders, Nico Hahn, Emma N Bos, Deni M van Schie, Isaac J Nijman, Nicole C T van Grieken, Donald L van der Peet, Hanneke W M van Laarhoven, Joep Grootjans, Maarten F Bijlsma, Jan Van den Bossche, Tanja D de Gruijl, Sarah Derks","doi":"10.1038/s41416-026-03635-3","DOIUrl":"https://doi.org/10.1038/s41416-026-03635-3","url":null,"abstract":"<p><strong>Background: </strong>The tumour immune microenvironment influences neoadjuvant chemoradiotherapy success in esophageal adenocarcinoma (EAC). Complete responders show higher treatment-naïve intratumoral CD8+ T cell levels before treatment than non-complete responders. Understanding mechanisms driving CD8+ T cells exclusion from the TIME is essential to improving outcomes.</p><p><strong>Methods: </strong>We performed spatial transcriptomics on treatment-naive CD8-low and high EACs (N = 12). Regions of interest (ROIs) were selected based on tumour annotation by a pathologist. Cancer (CK+) cells and immune (CD45+) cells were analysed within the same ROI. Findings were validated using bulk transcriptome data (TCGA) and metabolic profiling (SCENITH) of fresh tumour specimen (n = 5).</p><p><strong>Results: </strong>Whole transcriptomic profiling showed cancer cell clustering based on T cell infiltration. Cancer cell transcriptomes of CD8-low tumours exhibited reduced antigen presentation and upregulated lipid and mitochondrial metabolism, while CD8-high tumours showed increased cytokine signalling and apoptotic pathways. In CD45+ compartments, CD8-low tumours were enriched for the PGC-1α pathway, linked to mitochondrial biogenesis and immunosuppressive myeloid populations. These findings were supported by TCGA data. SCENITH confirmed mitochondrial dependence of macrophages in CD8-low tumours.</p><p><strong>Conclusion: </strong>Our results suggest that mitochondrial metabolism and impaired antigen presentation contribute to T cell exclusion in EAC. These findings raise the hypothesis that targeting mitochondrial metabolism in these cancers can modulate the anti-tumour immune response and thereby improve the response to chemoradiotherapy.</p>","PeriodicalId":9243,"journal":{"name":"British Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":7.8,"publicationDate":"2026-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149236934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
CXCL14+ fibroblasts promote development of IBD-associated fibrosis and cancer by interacting with SPP1+ macrophages via collagen IV secretion. CXCL14+成纤维细胞通过胶原IV分泌与SPP1+巨噬细胞相互作用,促进ibd相关纤维化和癌症的发展。
IF 7.8 1区 医学
British Journal of Cancer Pub Date : 2026-10-17 DOI: 10.1038/s41416-026-03636-2
Haonan Zhang, Yulu Shi, Qiuyu Song, Na Li, Zhaoxian Lin, Qiusan Chen, Yi Yang, Yanjun Chen, Qian Liu, Yan Tan, Yifeng Zheng, Shanping Wang, Yan Sun, Xiaxi Li, Chengcheng He, Lanxiang Zhu, Mingsong Li
{"title":"CXCL14+ fibroblasts promote development of IBD-associated fibrosis and cancer by interacting with SPP1+ macrophages via collagen IV secretion.","authors":"Haonan Zhang, Yulu Shi, Qiuyu Song, Na Li, Zhaoxian Lin, Qiusan Chen, Yi Yang, Yanjun Chen, Qian Liu, Yan Tan, Yifeng Zheng, Shanping Wang, Yan Sun, Xiaxi Li, Chengcheng He, Lanxiang Zhu, Mingsong Li","doi":"10.1038/s41416-026-03636-2","DOIUrl":"https://doi.org/10.1038/s41416-026-03636-2","url":null,"abstract":"<p><strong>Background: </strong>The pathogenesis of inflammatory bowel disease (IBD) involves chronic inflammation of the gastrointestinal tract, which predisposes patients to an increased risk of fibrosis and cancer due to prolonged inflammatory stimulation. However, the specific mechanisms underlying secondary gastrointestinal carcinogenesis in individuals with IBD remain poorly elucidated, particularly due to a limited number of studies conducted at single-nuclei level.</p><p><strong>Methods: </strong>We investigated the dynamics and interactions of cell subtypes during the progression of IBD-associated cancers through comprehensive analysis including single-nuclei transcriptomics, spatial transcriptomics, ecological dynamic modelling, multiplex immunohistochemistry, in vitro co-culture and in vivo animal studies.</p><p><strong>Results: </strong>The results revealed that CXCL14+ fibroblasts, the primary source of collagen in the microenvironment, play a pivotal role in the inflammation-cancer transition. These fibroblasts progressively increase in abundance during this transition and secreted elevated levels of collagen IV. The increased presence of collagen IV promotes the recruitment and differentiation of SPP1+ macrophages. This interaction ultimately contributes to the development and progression of IBD-associated fibrosis and cancer transformation. Collagen IV, secreted by CXCL14+ fibroblasts, plays a pivotal role in promoting the transition from IBD to cancer. Inhibition of collagen IV secretion not only prevents fibrosis but also hinders the development of inflammation-cancer transition.</p><p><strong>Conclusion: </strong>Our findings are crucial for understanding the mechanisms underlying IBD-associated cancer and developing innovative therapeutic strategies. During the inflammation-cancer transition, activation of the SOX4 leads to increased COL4A1/A2 secretion by CXCL14+ fibroblasts, resulting in enhanced collagen IV synthesis. Collagen IV binds to ITGB1/CD44 receptors on SPP1+ macrophages and activates EGR1/2 to promote SPP1+ macrophage differentiation, while upregulating S100A10 and ANXA2. Activation of S100A10 and ANXA2 promotes recruitment of SPP1+ macrophages, which contributes to immune escape and secretion of oncogenes, thus further promoting fibrosis and tumorigenesis. In addition, SPP1+ macrophages further stimulate CXCL14+ fibroblasts to secrete COL4A1/A2 via TGF-β1, forming a feedback loop that amplifies interactions in the tumour microenvironment.</p>","PeriodicalId":9243,"journal":{"name":"British Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":7.8,"publicationDate":"2026-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149214964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Waiting times and determinants of delay for head and neck cancer in England-a population cohort study using real world data. 英国头颈癌的等待时间和延迟的决定因素——使用真实世界数据的人口队列研究。
IF 7.8 1区 医学
British Journal of Cancer Pub Date : 2026-10-16 DOI: 10.1038/s41416-026-03630-8
Farizeh Jashek-Ahmed, Orouba Almilaji, Thomas E Cowling, David W Hamilton, Kate Walker, Vinidh Paleri
{"title":"Waiting times and determinants of delay for head and neck cancer in England-a population cohort study using real world data.","authors":"Farizeh Jashek-Ahmed, Orouba Almilaji, Thomas E Cowling, David W Hamilton, Kate Walker, Vinidh Paleri","doi":"10.1038/s41416-026-03630-8","DOIUrl":"https://doi.org/10.1038/s41416-026-03630-8","url":null,"abstract":"<p><strong>Background: </strong>In Head and Neck Cancer (HNC), even short delays in treatment can worsen prognosis. We used real-world data to quantify waiting times and identify patient, tumour and health service factors associated with treatment delay in England.</p><p><strong>Methods: </strong>Using linked national datasets (Cancer Registry, Cancer Waiting Times, Hospital Episodes Statistics, Radiotherapy and Chemotherapy), we calculated waiting times from referral to first treatment (surgery or (chemo)radiation) and used multivariable logistic regression models to examine factors associated with delay.</p><p><strong>Results: </strong>Of 30,506 patients, 43% experienced treatment delay ( > 62 days from referral). Long delays ( > 90 days) affected 11% of patients treated with primary surgery and 20% of those receiving primary (chemo)radiation. Non-urgent referral (30% of patients) was the strongest predictor of long delay (aOR 4.07, CI: 3.54-4.68). Additional risk-factors included initial assessment at non-specialist (spoke) hospitals, non-oropharyngeal cancers, and higher socio-economic deprivation.</p><p><strong>Conclusions: </strong>Treatment delays in HNC are worsening, particularly for patients treated with primary (chemo)radiation. Referral route is the strongest determinant. Interventions should focus on optimising referral pathways, increasing awareness of HNC symptoms among the public and primary care, and acknowledging the different drivers of delay associated with surgery and (chemo)radiation therapy.</p>","PeriodicalId":9243,"journal":{"name":"British Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":7.8,"publicationDate":"2026-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149206436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Preclinical efficacy of a systemically-administered, second-generation STING agonist that promotes anti-tumour immunity in combination with radiotherapy. 一种系统给药的第二代STING激动剂的临床前疗效,该激动剂可促进抗肿瘤免疫与放疗联合使用。
IF 7.8 1区 医学
British Journal of Cancer Pub Date : 2026-10-15 DOI: 10.1038/s41416-026-03634-4
Malin Pedersen, Lisa C Hubbard, Shane Foo, Anton Patrikeev, Antonio Rullan, Holly Baldock, Christian Mandl, Paolo Chetta, Jehanne Hassan, Isaac Dean, Naomi Guppy, Philippe Slos, Charleen Chan Wah Hak, Elizabeth Appleton, Emmanuel C Patin, Rachel Hunt, Justin Weir, Masahiro Ono, Thorsten Oost, Ulrich Reiser, Thomas Zichner, Kevin Morse, Mary Murphy, Lingqi Luo, Reniqua House, Louise Giffin, Alan A Melcher, Anne Vogt, Sebastian Carotta, Kevin J Harrington
{"title":"Preclinical efficacy of a systemically-administered, second-generation STING agonist that promotes anti-tumour immunity in combination with radiotherapy.","authors":"Malin Pedersen, Lisa C Hubbard, Shane Foo, Anton Patrikeev, Antonio Rullan, Holly Baldock, Christian Mandl, Paolo Chetta, Jehanne Hassan, Isaac Dean, Naomi Guppy, Philippe Slos, Charleen Chan Wah Hak, Elizabeth Appleton, Emmanuel C Patin, Rachel Hunt, Justin Weir, Masahiro Ono, Thorsten Oost, Ulrich Reiser, Thomas Zichner, Kevin Morse, Mary Murphy, Lingqi Luo, Reniqua House, Louise Giffin, Alan A Melcher, Anne Vogt, Sebastian Carotta, Kevin J Harrington","doi":"10.1038/s41416-026-03634-4","DOIUrl":"https://doi.org/10.1038/s41416-026-03634-4","url":null,"abstract":"<p><strong>Background: </strong>As potent triggers of innate immunity, STING agonists hold promise as active immunotherapeutic agents for cancer treatment. Second-generation STING agonists, suitable for systemic delivery, are being investigated in preclinical research and have entered clinical trials. Here, the novel synthetic STING agonist, BI-1703880 (STINGa), was investigated for anti-tumour and immunological effects.</p><p><strong>Methods: </strong>We used human and murine immune and tumour cells to examine the effects of STINGa in vitro, and preclinical cancer mouse models to investigate effects in vivo.</p><p><strong>Results: </strong>We show that STINGa activates the STING pathway and results in a transient and dose-dependent upregulation and secretion of interferons and proinflammatory cytokines in vitro and in vivo. We show that intravenous administration of repeated dosing with low-dose STINGa is well tolerated. We report that radiotherapy (RT) and STING agonism synergises to generate innate immune cell and CD8+ T cell responses that control tumour growth. RT/STINGa upregulated PD-L1, PD-1 and CTLA-4 in the tumour microenvironment. Our findings show that combining RT/STINGa with immune checkpoint inhibitors further increases therapeutic benefit.</p><p><strong>Conclusions: </strong>Our data confirm STING as a therapeutic target in cancer and support the clinical development of BI1703880 STING agonist, thereby suggesting radiotherapy as a potential combination for enhancing anti-tumour efficacy.</p>","PeriodicalId":9243,"journal":{"name":"British Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":7.8,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149191209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Retraction Note: Chromatin structure, transcriptional activity and DNA repair efficiency affect the outcome of chemotherapy in multiple myeloma 备注:染色质结构、转录活性和DNA修复效率影响多发性骨髓瘤化疗的结果。
IF 7.8 1区 医学
British Journal of Cancer Pub Date : 2026-10-15 DOI: 10.1038/s41416-026-03646-0
M. Gkotzamanidou, P. P. Sfikakis, S. A. Kyrtopoulos, C. Bamia, M. A. Dimopoulos, V. L. Souliotis
{"title":"Retraction Note: Chromatin structure, transcriptional activity and DNA repair efficiency affect the outcome of chemotherapy in multiple myeloma","authors":"M. Gkotzamanidou,&nbsp;P. P. Sfikakis,&nbsp;S. A. Kyrtopoulos,&nbsp;C. Bamia,&nbsp;M. A. Dimopoulos,&nbsp;V. L. Souliotis","doi":"10.1038/s41416-026-03646-0","DOIUrl":"10.1038/s41416-026-03646-0","url":null,"abstract":"","PeriodicalId":9243,"journal":{"name":"British Journal of Cancer","volume":"135 10","pages":"1755-1755"},"PeriodicalIF":7.8,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.comhttps://www.nature.com/articles/s41416-026-03646-0.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149191269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Paediatric therapeutic development workshop on desmoplastic small round cell tumours. 结缔组织增生小圆细胞肿瘤儿科治疗发展研讨会。
IF 7.8 1区 医学
British Journal of Cancer Pub Date : 2026-10-14 DOI: 10.1038/s41416-026-03631-7
Joseph S Baxter, Jan J Molenaar, Arushi Agrawal, Ana Teresa Amaral, Patricia Blanc, Nikki Bowdidge, Richard Bowdidge, Bernadette Brennan, Michela Casanova, David da Silva Moura, Sam Daems, Laura Danielson, Solomon English, Patrick Grohar, Emma Halliwell, Paul Huang, Pamela Kearns, Christopher A Klebanoff, Konstantinos Klaourakis, Marc Ladanyi, Geffen Lass, Katerina Lawlor, Corinne M Linardic, Joseph Ludwig, Stella Man, Leo Mascarenhas, Lucy Metayer, Michael Torsten Meister, Veronique Minard-Colin, Siwan Oldham, Daniel Orbach, Sheena Patel, Sandro Pasquali, Reineke A Schoot, Rob Sellar, Janet Shipley, Monika Sparber-Sauer, Silvia Stacchiotti, William Tap, Giovana Tardin Torrezan, Danh D Truong, Marc van de Wetering, Madina Wane, Joshua J Waterfall, Aaron Weiss, Janet Vasquez-Campbell, Andrew Dj Pearson, David Jenkinson, Andrea Ferrari, Sophie Postel-Vinay, Emily Slotkin
{"title":"Paediatric therapeutic development workshop on desmoplastic small round cell tumours.","authors":"Joseph S Baxter, Jan J Molenaar, Arushi Agrawal, Ana Teresa Amaral, Patricia Blanc, Nikki Bowdidge, Richard Bowdidge, Bernadette Brennan, Michela Casanova, David da Silva Moura, Sam Daems, Laura Danielson, Solomon English, Patrick Grohar, Emma Halliwell, Paul Huang, Pamela Kearns, Christopher A Klebanoff, Konstantinos Klaourakis, Marc Ladanyi, Geffen Lass, Katerina Lawlor, Corinne M Linardic, Joseph Ludwig, Stella Man, Leo Mascarenhas, Lucy Metayer, Michael Torsten Meister, Veronique Minard-Colin, Siwan Oldham, Daniel Orbach, Sheena Patel, Sandro Pasquali, Reineke A Schoot, Rob Sellar, Janet Shipley, Monika Sparber-Sauer, Silvia Stacchiotti, William Tap, Giovana Tardin Torrezan, Danh D Truong, Marc van de Wetering, Madina Wane, Joshua J Waterfall, Aaron Weiss, Janet Vasquez-Campbell, Andrew Dj Pearson, David Jenkinson, Andrea Ferrari, Sophie Postel-Vinay, Emily Slotkin","doi":"10.1038/s41416-026-03631-7","DOIUrl":"https://doi.org/10.1038/s41416-026-03631-7","url":null,"abstract":"<p><p>The sixth Paediatric Therapeutic Development Workshop focused on desmoplastic small round cell tumours (DSRCT). Less than 20% of patients with DSRCT survive beyond 5 years and there is no targeted therapy for this disease, which represents an urgent unmet need for new therapeutics. High priority targets include the EWSR1::WT1 fusion protein, the oncogenic driver, and targeting a junction-derived neopeptide presented by HLA-A*03 and HLA-A*11 using a T-cell receptor (TCR) is a novel approach. Other targets (LRRC15, SSTR3 and SSTR5, NECTIN4, STEAP1 and mesothelin) require further validation. Targeting ERBB2/HER2 or claudin-6 by antibody-drug conjugates (ADCs) and NTRK3 by a small molecule inhibitor are promising approaches and are currently being evaluated. Existing clinical assets targeting (in order of importance) B7-H3, the DNA damage response, androgen signalling, FGFR4 and STEAP1 are also high priorities for evaluation in DSRCT, but obtaining therapeutics for clinical trials is a barrier. In view of the rarity of DSRCT, a global initiative in preclinical and clinical research to establish international trials and collect data from patients treated in a harmonised form would benefit patients. Progress can be made by a combined approach of developing new agents whilst evaluating existing therapeutics in well-designed trials.</p>","PeriodicalId":9243,"journal":{"name":"British Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":7.8,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149179603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书